| Target Price | $724.20 |
| Price | $560.38 |
| Potential | 29.23% |
| Number of Estimates | 16 |
| 16 Analysts have issued a price target IDEXX Laboratories 2027 . The average IDEXX Laboratories target price is $724.20. This is 29.23% higher than the current stock price. The highest price target is $845.25 50.84% , the lowest is $477.17 14.85% . | |
| A rating was issued by 22 analysts: 14 Analysts recommend IDEXX Laboratories to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2027 of 29.23% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
19 Analysts have issued a sales forecast IDEXX Laboratories 2026 . The average IDEXX Laboratories sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
16 Analysts have issued an IDEXX Laboratories EBITDA forecast 2026. The average IDEXX Laboratories EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
18 IDEXX Laboratories Analysts have issued a net profit forecast 2026. The average IDEXX Laboratories net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
18 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is
. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .This results in the following potential growth metrics and future valuations:
IDEXX Laboratories...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Oct 16 2026 |
| Keybanc |
➜
Sector Weight
|
Initiated | Oct 12 2026 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Aug 11 2026 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 05 2026 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 05 2026 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Jul 27 2026 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Apr 28 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Oct 16 2026 |
|
Initiated
Keybanc:
➜
Sector Weight
|
Oct 12 2026 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Aug 11 2026 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 05 2026 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 05 2026 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Jul 27 2026 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Apr 28 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


